ERBB2 (D769Y)
Sign in to save this workspaceERBB2 · Variant type: point · HGVS: p.D769Y
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Osimertinib | 100.0% | 0.0% | 97.24 |
| 2 | Dacomitinib | 99.9% | 0.1% | 97.99 |
| 3 | Mobocertinib | 99.7% | 0.3% | 97.22 |
| 4 | Canertinib | 99.6% | 0.4% | 96.49 |
| 5 | Afatinib | 99.3% | 0.7% | 98.50 |
| 6 | Lazertinib | 99.2% | 0.8% | 97.47 |
| 7 | Pralsetinib | 98.9% | 1.1% | 93.43 |
| 8 | Darovasertib | 92.5% | 7.5% | 96.99 |
| 9 | Neratinib | 92.4% | 7.6% | 93.18 |
| 10 | Gefitinib | 91.5% | 8.5% | 99.25 |
| 11 | Brigatinib | 89.8% | 10.2% | 82.96 |
| 12 | Bosutinib | 88.8% | 11.2% | 87.22 |
| 13 | Ibrutinib | 88.4% | 11.6% | 94.74 |
| 14 | Lapatinib | 85.3% | 14.7% | 99.25 |
| 15 | Erlotinib | 83.9% | 16.1% | 99.75 |
| 16 | Fostamatinib | 79.0% | 21.0% | 96.74 |
| 17 | Avapritinib | 75.2% | 24.8% | 97.73 |
| 18 | Vandetanib | 73.2% | 26.8% | 95.74 |
| 19 | Alectinib | 44.8% | 55.2% | 95.49 |
| 20 | Dasatinib | 39.9% | 60.1% | 87.97 |
| 21 | Pacritinib | 29.0% | 71.0% | 88.64 |
| 22 | Alpelisib | 18.1% | 81.9% | 97.22 |
| 23 | Nintedanib | 14.9% | 85.1% | 90.23 |
| 24 | Ponatinib | 13.4% | 86.6% | 78.23 |
| 25 | Tivozanib | 9.8% | 90.2% | 92.42 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Osimertinib | 100.0% | — | — |
| Dacomitinib | 99.9% | — | — |
| Mobocertinib | 99.7% | — | — |
| Canertinib | 99.6% | — | — |
| Afatinib | 99.3% | — | — |
| Lazertinib | 99.2% | — | — |
| Pralsetinib | 98.9% | — | — |
| Darovasertib | 92.5% | — | — |
| Neratinib | 92.4% | — | — |
| Gefitinib | 91.5% | — | — |
| Brigatinib | 89.8% | — | — |
| Bosutinib | 88.8% | — | — |
| Ibrutinib | 88.4% | — | — |
| Lapatinib | 85.3% | — | — |
| Erlotinib | 83.9% | — | — |
| Fostamatinib | 79.0% | — | — |
| Avapritinib | 75.2% | — | — |
| Vandetanib | 73.2% | — | — |
| Alectinib | 44.8% | — | — |
| Dasatinib | 39.9% | — | — |
| Pacritinib | 29.0% | — | — |
| Alpelisib | 18.1% | — | — |
| Nintedanib | 14.9% | — | — |
| Ponatinib | 13.4% | — | — |
| Tivozanib | 9.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_breast | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.4ms